SAVSU Technologies Awarded New Patent for Cold Chain Technologies Used in Cell and Gene Therapies

ALBUQUERQUE, N.M., July 31, 2018 /PRNewswire/ -- SAVSU Technologies, the leading developer of smart, precision biologic shipping containers and cloud-based cold chain management SaaS solutions, today announced that the USPTO has issued a notice of allowance of patent number 10,018,614 B2, titled "Biologic Stability, Delivery Logistics and Administration of Time and/or Temperature Sensitive Biologic Based Materials". The inventors are Bruce McCormick, President of SAVSU Technologies, and Mike Rice, CEO of BioLife Solutions (NASDAQ:BLFS).

SAVSU has been granted 3 patents and has 6 other pending patent applications related to novel innovations incorporated into current, or to be incorporated into future, precision thermal shipping containers under the evo brand, including models that precisely maintain biologic payload temperature stability across the entire shipping continuum including -196°C using liquid nitrogen dry vapor shippers, -80°C using dry ice, and 2° - 8°C and controlled room temperature (CRT) using conditioned phase change insulating materials. These patent applications also include claims related to the evo.is Cold Chain Software as a Service (SaaS) live cell visibility platform.

Bruce McCormick, commented, "This patent grant further validates our mission to offer truly innovative biopreservation tools for regenerative medicine, with a focused and intentional goal to improve cold chain logistics of cell and gene therapies.  We believe the advanced and innovative evo hardware and software technologies will have tremendous impact on the preservation, delivery, and quality management of these precious, time and temperature sensitive biologic medicines."

About SAVSU

SAVSU is a leading designer and manufacturer of innovative high-performance cloud-connected passive storage and transport containers for temperature sensitive biologics and pharmaceuticals. Our mission is to improve global health by greatly reducing the waste and risks associated with the improper freezing and overheating of thermal-sensitive medicines and biologics. SAVSU has developed proprietary state-of-the-art technology to ultimately lower costs and improve delivery of these most essential materials. For more information please visit www.savsu.com.

SOURCE SAVSU Technologies

Related Links

http://www.savsu.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED